Delgocitinib cream had superior efficacy and a better safety profile compared with oral alitretinoin for the treatment of ...

The Chronic Hand Eczema market growth is driven by factors like increase in the prevalence of Chronic Hand Eczema, ...

“The discussion of delgocitinib and the presentation of DELTA FORCE data in The Lancet is an exciting moment for the LEO Pharma team,” said Robert Spurr, EVP, LEO Pharma, North America and ...

Dermatology specialist LEO Pharma has built the case for its first-in-class chronic hand eczema (CHE) drug delgocitinib, saying it outperformed the only approved drug therapy for the condition in ...

More than 90% of dermatology clinicians surveyed by Leo Pharma say their patients with moderate to severe chronic hand eczema ...

Delgocitinib cream is efficacious and well-tolerated for the treatment of adults with chronic hand eczema for up to 52 weeks.

This is the second of two phase 3 delgocitinib cream trials to achieve ... global research & development, LEO Pharma. "It is incredibly exciting to see the level of consistency that our DELTA ...

DELTA FORCE is the first head-to-head phase 3 trial comparing a systemic and investigational delgocitinib topical treatment for Chronic Hand Eczema (CHE).1 LEO Pharma A/S, a global leader in ...

DELTA FORCE is the first head-to-head phase 3 trial comparing a systemic and investigational delgocitinib topical treatment for Chronic Hand Eczema (CHE).1 ...